Oncimmune

Please note: The information displayed on this page might be outdated.
Oncimmune: Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. Oncimmune has a diversified and growing revenue from its portfolio of diagnostic products to detect early-stage cancer and a contract discovery and development service-based platform, delivering actionable insights into therapies to its pharmaceutical and biotech partners.

Oncimmune’s ImmunoINSIGHTS platform enables life-science organisations to optimise drug development and delivery, leading to more effective, targeted, as well as safer treatments for patients. Oncimmune's immunodiagnostic product, EarlyCDT, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programmes, globally.

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a partner representative office in Shanghai, China.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe, Other, United Kingdom
Disease Space
Autoimmune, Immuno-Oncology, Infectious Disease
Listing
Europe, Public
Market Cap
100MM - 500MM
Website:
Address:
MediCity, 1 Thane Road
Nottingham, NG90 6BH
United Kingdom

Company Participants at European Biotech Investor Days 2021

Adam M Hill, Dr
Oncimmune, CEO
Adam is a dual-qualified Clinician and Mechanical Engineer with a career built at the interface of industry, academia and health systems. Over the last 2 decades he has trained in surgery in the British Army; founded a successful applied research centre at Imperial College London; provided growth strategy and investment advice to global life science companies on behalf of the British Government; led the global medical function of a multinational, publicly-listed health IT company; and pivoted a Formula One team into a developer of health technology. Currently, Adam sits on the board of the ABHI, is a Visiting Professor in Global Health Innovation at Imperial College London and a Non-Executive Director of Imperial College Health Partners and MyRecovery.ai. Adam graduated from Imperial College London as a Medical Doctor whilst also earning a PhD in Engineering, attending Imperial College Business School and the Royal Military Academy Sandhurst. He received his postgraduate clinical training from the Royal College of Surgeons of England, and professional engineering qualification from the Institution of Mechanical Engineers.

Upcoming Company Event Participation

Top 10 Holders of Oncimmune Holdings Plc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Ruffer LLP 4.71 3,000,000 0.00 Stakes 5/31/20
Chelverton Asset Management Ltd. 3.68 2,340,190 0.00 Funds 6/30/20
Miton Asset Management Ltd. 3.25 2,070,457 0.00 Stakes 5/31/20
Aviva Investors Global Services Ltd. 0.26 162,701 0.00 Funds 6/30/20
Castlebay Investment Partners LLP 0.09 60,000 0.00 Funds 1/29/21
Gabelli Funds LLC 0.01 4,000 0.00 Funds 6/30/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.